Lupin, one of the leading pharmaceutical companies in India, witnessed a rise in share price on Friday after the company announced the acquisition of 100% equity stake in ZAO 'Biocom' in Russia subject to certain closing conditions.

The acquisition marks Lupin's foray into the Russian pharmaceutical market which recorded RUB 765 billion or nearly USD 13.75 billion in sales, placing it as one of the top 10 pharmaceutical markets in the world in 2014, according to IMS Health.

Shares of Lupin are trading at Rs 1,915, up Rs 45.3, or 2.42% at the Bombay Stock Exchange (BSE) on Friday at 9:36 a.m.

Total volume of shares traded on the bourses today was lower by 88.42% to 133,471 compared with 22-day average volume of 1,153,031.